Kyntra Bio, Inc. (KYNB) Key Metrics
KYNB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $19.6M
- Enterprise value
- $79.7M
- P/E (TTM)
- —
- Forward P/E
- 61.3
- PEG ratio
- —
- Price / sales
- 4.3 10-yr median 9.1
- Price / book
- 80.4 10-yr median 7.4
- EV / EBITDA
- 44.1
- Dividend yield
- —
- Beta
- 1.05
KYNB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKYNB valuation Price multiples at each fiscal year-end price.
Price / sales+207.9%
5.5
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+247.2 pts
−13.6%
2025 · hover or tap a bar for each year
20162025
KYNB returns How much profit the business earns on the capital it uses.
Return on assets+124.7 pts
109.8%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+392.1 pts
−74.7%
2025 · hover or tap a bar for each year
20162025
Asset turnover−58.5%
0.04
2025 · hover or tap a bar for each year
20162025
KYNB per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−78.5%
$1.59
2025 · hover or tap a bar for each year
20162025
Earnings per share
$45.38
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.19
2025 · hover or tap a bar for each year
20162025
Book value per share
−$7.43
2025 · hover or tap a bar for each year
20162025
Dividends per share+75.2%
$0.98
2025 · hover or tap a bar for each year
20162025
Shares outstanding+1.0%
4.0M
2025 · hover or tap a bar for each year
20162025
KYNB financial health Debt, liquidity and how easily interest is covered.
Net debt−$26.0M
−$3.4M
2025 · hover or tap a bar for each year
20162025
Current ratio+129.8%
3.39
2025 · hover or tap a bar for each year
20162025
Interest coverage
-5.2
2025 · hover or tap a bar for each year
20162025
Debt / assets+109.9%
0.72
2025 · hover or tap a bar for each year
20162025
KYNB efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+509 days
941 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+1,740 days
2,264 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+2,621 days
2,891 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−372 days
313 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.3 pts
0.6%
2025 · hover or tap a bar for each year
20162025
KYNB valuation history
Fiscal year-endToday10-year median
KYNB returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KYNB debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KYNB cash returned to shareholders
DividendsBuybacksFree cash flow
KYNB price vs earnings per share
Share price at year-endEPS (right axis)
KYNB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $35.5M | $53.0M | $86.2M | $1.50B | $1.30B | $3.33B | $3.72B | $3.89B | $3.46B | $1.34B |
| Enterprise value | $32.1M | $75.6M | $21.1M | $1.17B | $996.7M | $2.69B | $3.23B | $3.37B | $2.82B | $1.19B |
| P/E ratio | 0.2 | — | — | — | — | — | — | — | — | — |
| Price / sales | 5.5 | 1.8 | 1.8 | 10.7 | 5.5 | 18.9 | 14.5 | 18.3 | 27.5 | 7.5 |
| Price / book | — | — | — | — | 6.2 | 7.9 | 7.2 | 7.6 | 6.1 | 8.6 |
| Price / free cash flow | — | — | — | — | — | 42.9 | — | — | — | 229.3 |
| Price / operating cash flow | — | — | — | — | — | 40.8 | — | — | — | 188.9 |
| EV / sales | 5.0 | 2.6 | 0.5 | 8.3 | 4.2 | 15.2 | 12.6 | 15.8 | 22.5 | 6.6 |
| EV / free cash flow | — | — | — | — | — | 34.6 | — | — | — | 202.7 |
| Earnings yield | 516.8% | −89.7% | −329.7% | −19.6% | −22.3% | −5.7% | −2.1% | −2.2% | −3.6% | −4.6% |
| Free cash flow yield | −13.6% | −260.8% | −368.3% | −12.3% | −8.6% | 2.3% | −2.3% | −2.2% | −2.2% | 0.4% |
| Dividend yield | 11.1% | 4.2% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 11.3% | 4.2% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $8.78 | $13.25 | $22.15 | $400.50 | $352.50 | $927.25 | $1,072.25 | $1,157.00 | $1,185.00 | $535.00 |
| Per share | ||||||||||
| Revenue per share | $1.59 | $7.40 | $12.03 | $37.60 | $63.70 | $49.06 | $74.04 | $63.33 | $43.04 | $71.55 |
| Earnings per share | $45.38 | −$11.89 | −$73.03 | −$78.45 | −$78.51 | −$52.67 | −$22.21 | −$25.70 | −$43.23 | −$24.58 |
| Operating cash flow per share | −$1.18 | −$34.48 | −$80.94 | −$38.99 | −$22.26 | $22.70 | −$22.71 | −$22.65 | −$22.78 | $2.83 |
| Free cash flow per share | −$1.19 | −$34.55 | −$81.59 | −$49.33 | −$30.43 | $21.59 | −$24.37 | −$25.03 | −$25.69 | $2.33 |
| Cash per share | $22.01 | $12.61 | $60.53 | $112.74 | $109.69 | $191.01 | $154.03 | $184.80 | $252.00 | $100.88 |
| Book value per share | −$7.43 | −$56.38 | −$52.46 | −$5.73 | $56.62 | $117.46 | $148.94 | $151.44 | $192.90 | $62.09 |
| Tangible book value per share | −$7.43 | −$56.38 | −$52.46 | −$5.73 | $56.62 | $117.46 | $148.94 | $151.44 | $192.90 | $62.09 |
| Dividends per share | $0.98 | $0.56 | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.07 | $0.65 | $10.35 | $8.17 | $1.11 | $1.66 | $2.39 | $2.91 | $0.50 |
| Debt per share | $21.16 | $18.26 | $43.79 | $24.01 | $27.00 | $11.06 | $14.97 | $28.89 | $33.49 | $38.79 |
| Shares outstanding | 4.0M | 4.0M | 3.9M | 3.7M | 3.7M | 3.6M | 3.5M | 3.4M | 2.9M | 2.5M |
| Change in shares outstanding | +1.0% | +2.8% | +4.0% | +1.3% | +2.8% | +3.7% | +3.1% | +15.2% | +16.3% | +4.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −91.9% | −40.3% | −15.0% | −16.1% | −35.1% | −37.0% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −734.3% | — | — | −90.7% |
| Return on assets (ROA) | 109.8% | −14.9% | −55.0% | −42.4% | −36.2% | −22.5% | −8.9% | −9.7% | −18.4% | −13.1% |
| Return on tangible assets | 153.4% | −22.2% | −67.1% | −48.1% | −37.5% | −22.9% | −9.0% | −9.8% | −14.0% | −13.1% |
| Free cash flow margin | −74.7% | −466.8% | −678.5% | −131.2% | −47.8% | 44.0% | −32.9% | −39.5% | −59.7% | 3.3% |
| Income quality (OCF / net income) | −0.03 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $85.5M | $73.1M | $170.5M | $89.9M | $99.7M | $39.8M | $51.9M | $97.2M | $97.8M | $97.4M |
| Cash & short-term investments | $89.0M | $50.5M | $235.6M | $422.0M | $405.2M | $686.5M | $533.8M | $621.4M | $735.7M | $253.2M |
| Net debt | −$3.4M | $22.6M | −$65.1M | −$332.1M | −$305.5M | −$646.8M | −$481.9M | −$524.2M | −$638.0M | −$155.8M |
| Debt / equity | — | — | — | — | 0.48 | 0.09 | 0.10 | 0.19 | 0.17 | 0.62 |
| Debt / assets | 0.72 | 0.34 | 0.40 | 0.15 | 0.13 | 0.05 | 0.06 | 0.11 | 0.11 | 0.21 |
| Current ratio | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 9.69 | 4.09 |
| Quick ratio | 3.26 | 1.45 | 1.33 | 1.65 | 1.96 | 4.53 | 6.77 | 7.75 | 9.69 | 4.09 |
| Interest coverage | -5.2 | -18.2 | -39.9 | -209.0 | -268.4 | -79.9 | -31.1 | -7.9 | -12.6 | -5.0 |
| Working capital | $69.8M | $63.2M | $113.9M | $219.3M | $248.6M | $591.9M | $599.7M | $601.0M | $671.7M | $201.4M |
| Invested capital | −$33.5M | −$203.0M | −$269.3M | −$353.6M | −$96.3M | −$224.6M | $34.3M | −$15.0M | −$74.8M | $11,000 |
| Tangible asset value | $4.5M | −$183.6M | −$162.2M | −$1.5M | $229.1M | $441.4M | $535.4M | $528.5M | $582.5M | $175.1M |
| Net current asset value | −$16.0M | −$201.7M | −$254.2M | −$118.7M | −$70.6M | $369.7M | $380.5M | $337.9M | $432.8M | −$27.9M |
| Graham net-net per share | −$5.22 | −$81.06 | −$76.71 | −$41.97 | −$28.41 | $94.83 | $95.36 | $94.29 | $145.87 | −$13.32 |
| Capital allocation | ||||||||||
| Dividends paid | $3.9M | $2.2M | — | — | — | — | — | — | — | — |
| Share buybacks (net) | $69,000 | — | — | — | — | — | — | — | — | — |
| Dividend payout ratio | 2.2% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.6% | 0.9% | 5.4% | 27.5% | 12.8% | 2.3% | 2.2% | 3.8% | 6.8% | 0.7% |
| Capex / operating cash flow | — | — | — | — | — | 4.9% | — | — | — | 17.6% |
| Capex / depreciation | 0.05 | 0.10 | 0.25 | 3.65 | 2.04 | 0.18 | 0.27 | 1.22 | 1.39 | 0.21 |
| Stock-based compensation / revenue | 102.1% | 85.1% | 108.5% | 46.6% | 30.2% | 41.2% | 25.8% | 24.5% | 29.9% | 17.9% |
| R&D / revenue | 365.2% | 323.1% | 569.4% | 210.9% | 164.5% | 143.4% | 81.6% | 110.7% | 156.4% | 104.2% |
| SG&A / revenue | 430.3% | 166.5% | 184.8% | 88.6% | 52.7% | — | — | 30.0% | 41.2% | 25.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 940.8 | 431.5 | 223.6 | 54.1 | 52.2 | 202.4 | 154.6 | 61.8 | 27.4 | 26.3 |
| Days of inventory on hand | 2,264.2 | 524.5 | 3,777.2 | 643.0 | 19.3 | 481.9 | 2,191.6 | — | — | — |
| Days payables outstanding | 2,891.4 | 270.0 | 2,244.1 | 511.6 | 20.7 | 635.4 | 2,422.8 | 11.3 | 10.9 | 12.4 |
| Cash conversion cycle (days) | 313.5 | 685.9 | 1,756.7 | 185.4 | 50.8 | 48.9 | -76.6 | 50.5 | 16.6 | 13.9 |
| Receivables turnover | 0.39 | 0.85 | 1.63 | 6.75 | 6.99 | 1.80 | 2.36 | 5.90 | 13.30 | 13.89 |
| Payables turnover | 0.13 | 1.35 | 0.16 | 0.71 | 17.65 | 0.57 | 0.15 | 32.20 | 33.50 | 29.38 |
| Inventory turnover | 0.16 | 0.70 | 0.10 | 0.57 | 18.90 | 0.76 | 0.17 | — | — | — |
| Asset turnover | 0.04 | 0.09 | 0.09 | 0.20 | 0.29 | 0.21 | 0.30 | 0.24 | 0.18 | 0.38 |
| Average receivables | $16.6M | $35.0M | $28.7M | $20.9M | $33.6M | $97.8M | $108.7M | $36.1M | $9.4M | $12.9M |
| Average payables | $4.4M | $11.5M | $24.4M | $28.4M | $25.4M | $15.4M | $7.6M | $7.3M | $5.9M | $6.4M |
| Average inventory | $3.4M | $22.4M | $41.0M | $35.7M | $23.8M | $11.7M | $6.9M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KYNB's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KYNB valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Kyntra Bio traded at 0.2 times earnings. It ended the year with $85.5 million of debt and $89.0 million in cash and short-term investments, a net cash position of $3.4 million. It returned $4.0 million to shareholders: $3.9 million in dividends and $0.1 million in share buybacks. The share count rose 61.1% from 2.5M to 4.0M over 9 years.
See the KYNB income statement, the KYNB chart for price history, or the KYNB stock overview for the latest quote and news.
KYNB key metrics FAQ
What is Kyntra Bio's P/E ratio?
Kyntra Bio traded at 0.2 times earnings at the end of fiscal 2025.
How much debt does Kyntra Bio have?
Kyntra Bio had total debt of $85.5 million at the end of fiscal 2025 and more cash than debt.
What is Kyntra Bio's dividend yield?
Kyntra Bio paid $3.9 million in dividends in fiscal 2025 ($0.98 per share), a payout ratio of 2.2%.
Does Kyntra Bio buy back its shares?
Yes. Kyntra Bio spent $0.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +1.0% over the year, to 4.0M..
What is Kyntra Bio's free cash flow yield?
Kyntra Bio generated -$4.8 million of free cash flow in fiscal 2025, a free cash flow yield of −13.6% on its market value at year-end ($35.5 million).
What is Kyntra Bio's current ratio?
Kyntra Bio's current ratio was 3.39 at the end of fiscal 2025: current assets were 3.39 times current liabilities.